Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7381128 | 0.84 | TRPA1 (0.31) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL22229966 | 0.82 | GABBR2 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL16862540 | 0.81 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL29155901 | 0.80 | TSHR (0.37) | MEN1HTTKMT2AL3MBTL1TSHR | |
| SCHEMBL29155903 | 0.80 | TSHR (0.37) | MEN1HTTKMT2AL3MBTL1TSHR | |
| SCHEMBL2788268 | 0.79 | ACACB (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL18340854 | 0.79 | ACACB (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL13731404 | 0.78 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1952760 | 0.78 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1979048 | 0.78 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-02-15 | — | — | US | disclosed |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-09-17 | — | — | US | disclosed |
| WO-2011071716-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | MEN1 3650/4885HTT 4202/4885KMT2A 3057/4885 |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | MEN1 3832/4885HTT 3402/4885KMT2A 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.